Michael Gelband’s Cabaletta Bio CABA Stock Holding History

Michael Gelband’s Portfolio CABA Stock Details CABA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-105,985	Closed	-$285K	–	1609
2026 Q1	$285K	Buy	+105,985	New	+$294K	﹤0.01%	1318
2024 Q2	–	Sell	-53,342	Closed	-$910K	–	1553
2024 Q1	$910K	Buy	+53,342	New	+$1.14M	0.01%	981
2022 Q1	–	Sell	-10,414	Closed	-$39K	–	2219
2021 Q4	$39K	Buy	+10,414	New	+$111K	﹤0.01%	2054
2021 Q3	–	Sell	-33,857	Closed	-$291K	–	2148
2021 Q2	$291K	Buy	+33,857	New	+$333K	﹤0.01%	1761
2020 Q2	–	Sell	-15,668	Closed	-$114K	–	1781
2020 Q1	$114K	Buy	+15,668	New	+$215K	0.01%	872

Other funds holding CABA

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Michael Gelband's CABA Position: Q2 2026 in Review

Michael Gelband sold out of Cabaletta Bio (CABA) in Q2 2026, closing a stake of 105,985 shares — an estimated $285K sold.

Michael Gelband first reported a position in CABA in Q1 2020 and held it in 5 quarters. The position peaked at $910K in Q1 2024. 139 funds tracked by Wall St. Rank hold CABA as of Q2 2026.

Michael Gelband reported no remaining Cabaletta Bio position as of Q2 2026 after selling out during the quarter.
Michael Gelband sold 105,985 Cabaletta Bio shares in Q2 2026, an estimated $285K.
Michael Gelband first reported a position in Cabaletta Bio in Q1 2020 and held it in 5 quarters.
Michael Gelband's Cabaletta Bio position peaked at $910K in Q1 2024.
139 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.